Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

ABBV-295 for Weight Loss in Adults With Obesity or Overweight

Tests different doses of ABBV-295 against placebo for weight loss in adults.

Plain-language title generated from the registry record
Registry title: Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Key facts

Where
Amarillo, Arlington, Austin, Bellaire, Blackfoot, Bristol, Butte, Chicago, Cincinnati, City of Saint Peters, Clearwater, Concord, Costa Mesa, Dallas, Danville, Fargo, Fayette, Fleming Island, Greenbrae, Greensboro, Houston, Huntington Park, Jacksonville, Knoxville, Lake Worth, Las Vegas, Longview, Los Angeles, Louisville, Margate, Mesquite, Miramar, Monroe, Morehead City, Nashville, New Bern, New Port Richey, Newport News, Orlando, Pelham, Port Orange, Renton, Richmond, Rochester, Rolling Hills Estates, Roswell, Round Rock, Santa Ana, Scottsdale, Spring Valley, The Villages, Tucson, Tustin, Walnut Creek, West Palm Beach, Weston, and Wilmington, United StatesSee the 60 sites
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07752979, who can take part

Where in United States

  • Amarillo Medical Specialists /ID# 282380Amarillo, United StatesTaking people
  • Washington Center For Weight Management And Research /ID# 282047Arlington, United StatesTaking people
  • Elligo Clinical Research Center /ID# 282166Austin, United StatesTaking people
  • JCCT - Juno Bellaire /ID# 282263Bellaire, United StatesTaking people
  • Elite Clinical Trials - Blackfoot /ID# 282042Blackfoot, United StatesTaking people
  • Holston Medical Group - Bristol /ID# 282045Bristol, United StatesTaking people
  • Mercury Street Medical /ID# 282016Butte, United StatesTaking people
  • Great Lakes Clinical Trials - West Wilson Avenue /ID# 282378Chicago, United StatesTaking people
  • CTI Clinical Research Center /ID# 282043Cincinnati, United StatesTaking people
  • Studymetrix Research /ID# 282163City of Saint Peters, United StatesTaking people
  • Innovative Research of West Florida /ID# 281963Clearwater, United StatesTaking people
  • John Muir Health - Concord /ID# 282469Concord, United StatesTaking people
  • Aurora FDRC Inc. /ID# 282494Costa Mesa, United StatesTaking people
  • Velocity Clinical Research - Dallas /ID# 282734Dallas, United StatesTaking people
  • Sovah Health - Danville /ID# 282876Danville, United StatesTaking people
  • Lillestol Research LLC /ID# 281978Fargo, United StatesTaking people
  • Prime Health and Wellness /ID# 282254Fayette, United StatesTaking people
  • Northeast Research Institute (NERI) /ID# 282015Fleming Island, United StatesTaking people
  • NorCal Medical Research /ID# 283117Greenbrae, United StatesTaking people
  • Medication Management /ID# 281965Greensboro, United StatesTaking people
  • Juno Research /ID# 282413Houston, United StatesTaking people
  • PlanIt Research /ID# 282204Houston, United StatesTaking people
  • Velocity Clinical Research - Huntington Park /ID# 282987Huntington Park, United StatesTaking people
  • Encore Research Group-Jacksonville Center for Clinical Research /ID# 282740Jacksonville, United StatesTaking people
  • New Phase Research & Development /ID# 282131Knoxville, United StatesTaking people
  • Summit Medical Group- Halls Family Physicians /ID# 282435Knoxville, United StatesTaking people
  • Altus Clinical Research - Lake Worth - South Congress Avenue /ID# 281979Lake Worth, United StatesTaking people
  • Vector Clinical Trials /ID# 282265Las Vegas, United StatesTaking people
  • Dcol Center For Clinical Research /ID# 281961Longview, United StatesTaking people
  • Los Angeles Institute for Metabolic Research /ID# 282059Los Angeles, United StatesTaking people
  • L-MARC Research Center /ID# 282008Louisville, United StatesTaking people
  • South Florida Wellness & Clinic /ID# 282022Margate, United StatesTaking people
  • Southern Endocrinology Associates /ID# 282558Mesquite, United StatesTaking people
  • South Broward Research /ID# 282125Miramar, United StatesTaking people
  • Monroe Biomedical Research /ID# 282009Monroe, United StatesTaking people
  • Centricity Research - Morehead city /ID# 283264Morehead City, United StatesTaking people
  • Clinical Research Associates - Nashville /ID# 282161Nashville, United StatesTaking people
  • Lucas Research - New Bern /ID# 282747New Bern, United StatesTaking people
  • Suncoast Clinical Research Pasco County /ID# 282412New Port Richey, United StatesTaking people
  • Health Research Of Hampton Roads /ID# 282014Newport News, United StatesTaking people
  • Charter Research - Winter Park /ID# 281968Orlando, United StatesTaking people
  • Florida Institute For Clinical Research /ID# 282739Orlando, United StatesTaking people
  • Cahaba Research - Pelham /ID# 282381Pelham, United StatesTaking people
  • Progressive Medical Research /ID# 282838Port Orange, United StatesTaking people
  • Rainier Clinical Research /ID# 282157Renton, United StatesTaking people
  • National Clinical Research /ID# 282007Richmond, United StatesTaking people
  • Rochester Clinical Research /ID# 282484Rochester, United StatesTaking people
  • Peninsula Research Associates /ID# 282158Rolling Hills Estates, United StatesTaking people
  • Endocrine Research Solutions /ID# 282020Roswell, United StatesTaking people
  • Texas Diabetes and Endocrinology /ID# 282291Round Rock, United StatesTaking people
  • Southern California Dermatology /ID# 282011Santa Ana, United StatesTaking people
  • Headlands Research - Scottsdale /ID# 282571Scottsdale, United StatesTaking people
  • Encompass Clinical Research /ID# 282483Spring Valley, United StatesTaking people
  • Charter Research - The Villages /ID# 282376The Villages, United StatesTaking people
  • Arizona Clinical Trials /ID# 282372Tucson, United StatesTaking people
  • University Clinical Investigators /ID# 282132Tustin, United StatesTaking people
  • Diablo Clinical Research /ID# 282530Walnut Creek, United StatesTaking people
  • Metabolic Research Institute /ID# 282350West Palm Beach, United StatesTaking people
  • Encore Medical Research - Weston /ID# 282044Weston, United StatesTaking people
  • Accellacare - Tradd Court - Wilmington /ID# 282200Wilmington, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
AbbVie
Trial code
NCT07752979
Record updated
27 October 2026
Original description
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight with weight-related comorbidities.Read full original descriptionShow less

A Phase 2 Dose-Finding Study to Assess the Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight with weight-related comorbidities.

ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management. Participants are placed into multiple treatment groups with different dosing paradigms of ABBV-295 or placebo. Participants will not know which treatment they are receiving, and there is a chance of being assigned to placebo. Adults with obesity or overweight (as defined by BMI) with weight-related comorbidities will be enrolled. Approximately 360 participants will be enrolled in the study at approximately 70 sites in the United States and Puerto Rico.

Participants will receive subcutaneous (SC) injections of ABBV-295 solution for injection or matching placebo administered via pre-filled syringes for 52 weeks during the Double-Blind Period.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Inclusion: BMI ≥ 30.0 kg/m2 at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) OR; BMI ≥ 27.0 to < 30.0 kg/m2 at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with at least one of the following weight-related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD).

Exclusion: Self-reported change in body weight ≥ 5% within 3 months prior to Screening; Treatment with any medication or product used for obesity or weight management within 180 days prior to Screening Unstable or severe cardiovascular disease (e.g., myocardial infarction, stroke, hospitalization for: unstable angina pectoris, transient ischemic attack, or heart failure) within 180 days prior to Screening; The participant has a concurrent disease, condition, or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study; History of type 1 or type 2 diabetes mellitus; Hemoglobin A1c (HbA1c) ≥ 6.5% (48 mmol/mol) at Screening; Fasting glucose ≥126 mg/dL (7.0 mmol/L) or random glucose test ≥ 200 mg/dL (11.1 mmol/L).

ClinicalTrials.gov NCT07752979